The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 30, 2018

Filed:

Mar. 26, 2015
Applicant:

Ablynx N.v., Zwijnaarde, BE;

Inventor:

Karen Silence, Overijse, BE;

Assignee:

Ablynx, N.V., Ghent-Zwijnaarde, BE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/18 (2006.01); A61K 38/16 (2006.01); A61K 38/49 (2006.01); C07K 16/28 (2006.01); C07K 16/36 (2006.01); G01N 33/86 (2006.01); A61K 45/06 (2006.01); A61L 29/08 (2006.01); A61L 29/16 (2006.01); A61L 31/10 (2006.01); A61L 31/16 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 38/166 (2013.01); A61K 38/49 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61L 29/085 (2013.01); A61L 29/16 (2013.01); A61L 31/10 (2013.01); A61L 31/16 (2013.01); C07K 16/2896 (2013.01); C07K 16/36 (2013.01); G01N 33/68 (2013.01); G01N 33/6893 (2013.01); G01N 33/86 (2013.01); A61K 2039/505 (2013.01); A61L 2300/256 (2013.01); A61L 2300/42 (2013.01); A61L 2420/02 (2013.01); C07K 2317/22 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/569 (2013.01); G01N 2333/47 (2013.01); G01N 2333/755 (2013.01); G01N 2500/02 (2013.01); G01N 2500/04 (2013.01); G01N 2800/222 (2013.01);
Abstract

The present invention relates to polypeptides comprising at least one single domain antibody directed against vWF, vWF A1 domain, A1 domain of activated vWF, vWF A3 domain, gpIb and/or collagen, homologs of said polypeptides, and/or functional portions of said polypeptides, for the treatment for conditions which require a modulation of platelet-mediated aggregation and which overcomes the problems of the prior art. A further aspect of the invention is methods of production of said polypeptides, methods to coat devices with such polypeptides used in medical procedures (e.g. PCTA, stenting), methods and kits for screening for agents that modulate platelet-mediated aggregation and kits for the diagnosis of diseases related to platelet-mediated aggregation.


Find Patent Forward Citations

Loading…